Eisai Enters into License Agreement for the Development and Distribution of Fibroblast Growth Factor (FGF) Receptor Selective Tyrosine Kinase Inhibitor Tasurgratinib in Greater China Region (Mainland China, Hong Kong, Macau, and Taiwan) with SciClone

TOKYO, Feb 28, 2025 – (JCN Newswire via SeaPRwire.com) – Eisai Co., Ltd. announced today that the company has entered into a license agreement granting the exclusive development and distribution rights …